Sofia, Bulgaria 26 January 2024 - According to the requirements of Art. 89t of the LPOS, "Sopharma" AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies all interested parties that the Company (on the basis of Art. 89t of the Law on the Public Offering of Securities, in connection with the decision of the General Meeting of Warrant Holders (GMWH) dated 26.01.2024 and decision of the Board of Directors of "SOPHARMA" AD dated 26.01.2024 and on the basis of Art. 195 and 196 of the Commercial Law (CL), Art. 113, para. 2, it. 2 of the LPOS and Art.

Sofia, Bulgaria, January 22, 2024 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for December 2023 the Company recorded a decrease in sales of 57% compared to the same month of the previous year, incl. 27% decrease in domestic sales and 68% decrease in export sales.

For 2023 the revenues from sales of products increase by 7%, incl. 1% increase of sales for the domestic market and 11% increase in export sales.

Sofia, Bulgaria, 15 January 2024 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE” AD, SPH: Warsaw Stock Exchange) notifies that the Board of Directors of "Sopharma" AD adopted a decision to initiate a procedure for the merger of the subsidiary "Veta pharma" AD, UIC: 104111084 in "Sopharma" AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on the Public Offering of Securities. At the start of the procedure Sopharma AD owns 99.98% in the capital of the company.